Sofia Fund

Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts

by | Jul 16, 2019 | Sofia Fund News

Investigating Quantitative EEG as Biomarker of Patient Response to Treatment in Future Efficacy Studies

Pittsburgh, PA, July 09, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the receipt of a grant expected to total $3.3 million from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to conduct a clinical trial (COG0202) in which quantitative electroencephalography (qEEG) will be used to measure changes in synaptic activity in individuals with Alzheimer’s disease who have been treated with Cognition’s lead candidate, Elayta™.…

Sofia Fund Expands to Kansas City

by | Jul 9, 2019 | Sofia Fund News

Angel investment firm names McCoolidge managing partner

Minneapolis, MN, June 26, 2019 — Minneapolis-based Sofia Fund is expanding to the Kansas City market. To establish its presence in the area, which is a hub of startup activity, it has added a Kansas City-based partner, Laura McCoolidge.…

Steps to Success: Reasonable Valuations

by | Jun 24, 2019 | Sofia Fund Blog

Second blog in a series by Lisa Crump, founder of Cairn Ventures and Managing Partner, Sofia Fund. View Part I here. View Part III here.

Steps to Success incorporates advice and views in a short series of blogs, based on my experience as a tech entrepreneur and now angel investor, specifically focused on women-led startups.…

Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer

by | Jun 6, 2019 | Portfolio Company News

Pittsburgh, PA, June 05, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., today announced that Anthony O. Caggiano, M.D., Ph.D. has joined the Company as chief medical officer (CMO). Cognition Therapeutics is a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative diseases and disorders caused by toxic oligomeric proteins.…

JoyLux Named Most Innovative Company of 2019 by Angel Capital Association

by | May 23, 2019 | Portfolio Company News

Winner of the prestigious Luis Villalobos Award, honoring ingenuity and innovation among start up companies.

Seattle, WA, April 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve women’s intimate health, has been named the most innovative company by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…

Getting to Success: Advice from a Tech Entrepreneur Turned Angel

by | Apr 22, 2019 | Sofia Fund Blog

First blog in a series by Lisa Crump, founder of Cairn Ventures and Managing Partner, Sofia Fund. View Part II here. View Part III here.

As co-founder of Stratasys, Inc., a pioneering 3D printing technology company, I worked with a team of remarkable, risk-taking contributors – talented employees and managers, skilled board members and advisors, early investors, far-sighted customers, supportive vendors and a visionary co-founder.…

Joylux Named One of The Top Three Most Innovative Companies by Angel Capital Association

by | Mar 26, 2019 | Portfolio Company News

Joylux to be honored at the Angel Capital Association’s 2019 Summit as a top-three finalist for the prestigious Luis Villalobos Award

Seattle, WA, March 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve vaginal health for postpartum and menopausal women, has been named one of the top three most ingenious and innovative companies funded by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…